Oramed Pharmaceuticals Inc. (ORMP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Oramed Pharmaceuticals reported revenue of $2.0M. Net income was $64.0M (a 3202.5% net margin), or $1.50 per diluted share. Gross margin was 0.7% and operating margin was -754.4%. Operating activities generated -$9.1M of cash, leaving -$9.2M of free cash flow. At fiscal year end, Oramed Pharmaceuticals held $230.9M in total assets against $31.1M in total liabilities, including $45.9M of cash and equivalents.
Open the full interactive Oramed Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Oramed Pharmaceuticals Key Stats
| Share Price | $4.17 |
|---|---|
| Market Cap | $177.2M |
| P/E Ratio | 2.8 |
| 52-Week Range | $2.04 – $5.34 |
| Shares Outstanding | 41.0 million (basic, 2026 Q2) |
Oramed Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.7M | $2.7M | $2.7M | $1.3M | — | $2.0M |
| Gross Profit | $2.7M | — | — | — | — | $13,000 |
| Operating Income | -$11.8M | -$24.2M | -$40.6M | -$15.8M | -$12.8M | -$15.1M |
| Pre-Tax Income | -$11.5M | $23.0M | -$37.7M | $5.1M | -$15.9M | $75.3M |
| Income Tax | — | $46.0M | $100,000 | -$437,000 | $3.2M | $11.3M |
| Net Income | -$11.5M | -$23.0M | -$37.8M | $5.5M | -$19.1M | $64.0M |
| Diluted EPS | $0.56 | $0.78 | $0.94 | $0.14 | -$0.48 | $1.50 |
Oramed Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | $48.4M | $10.0M | $38.3M | $78.2M |
| Diluted EPS | $1.13 | $0.24 | $0.91 | $1.84 |
Oramed Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.3M | $77.2M | — | $9.1M | — | $45.9M |
| Current Assets | $40.5M | $95.3M | $157.1M | $162.6M | $143.2M | $133.3M |
| Total Assets | $44.6M | $128.0M | $161.6M | $220.6M | $155.3M | $230.9M |
| Current Liabilities | $4.5M | $6.7M | $5.7M | $53.2M | $5.7M | $19.1M |
| Total Long-Term Debt | $3.9M | — | $25,000 | — | — | — |
| Total Liabilities | $11.8M | $12.2M | $9.8M | $56.7M | $9.0M | $31.1M |
| Shareholders' Equity | $32.9M | $115.8M | $151.8M | $163.8M | $146.3M | $199.7M |
Oramed Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$12.4M | -$21.2M | -$27.9M | -$10.3M | -$8.4M | -$9.1M |
| Cash From Investing | $4.6M | -$23.8M | $30.2M | -$73.0M | $105.8M | $5.4M |
| Cash From Financing | $23.8M | $102.9M | $10.8M | $52.0M | -$52.0M | -$4.7M |
| Free Cash Flow | -$12.5M | -$21.6M | -$28.4M | -$10.5M | -$8.4M | -$9.2M |
Figures from Oramed Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Oramed Pharmaceuticals financials page for every line item.
Oramed Pharmaceuticals Company Profile
| Ticker | ORMP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001176309 |
Frequently Asked Questions
What was Oramed Pharmaceuticals' revenue in fiscal 2025?
Oramed Pharmaceuticals (ORMP) reported revenue of $2.0M for fiscal 2025.
What is Oramed Pharmaceuticals' annual revenue history?
Oramed Pharmaceuticals' annual revenue by fiscal year: 2020: $2.7M; 2021: $2.7M; 2022: $2.7M; 2023: $1.3M; 2025: $2.0M.
What was Oramed Pharmaceuticals' net income in fiscal 2025?
Oramed Pharmaceuticals reported net income of $64.0M for fiscal 2025.
What was Oramed Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Oramed Pharmaceuticals' diluted EPS was $1.50 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Oramed Pharmaceuticals generate in fiscal 2025?
Oramed Pharmaceuticals generated -$9.2M of free cash flow in fiscal 2025.
How many shares of Oramed Pharmaceuticals are outstanding?
Oramed Pharmaceuticals reported a weighted average of 41.0 million basic shares outstanding in 2026 Q2.
What is Oramed Pharmaceuticals' market cap?
Based on its latest closing price, Oramed Pharmaceuticals (ORMP) has a market capitalization of about $177.2M.
When does Oramed Pharmaceuticals' fiscal year end?
Oramed Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Oramed Pharmaceuticals headquartered?
Oramed Pharmaceuticals lists its business address in New York, New York in its SEC filings.